Investors, Partners
& Collaborators
Grannus offers a compelling investment and collaboration opportunity in precision oncology. Our Hsp90β-selective platform solves a decades-long problem with a safe, targeted, and clinically viable approach to a validated cancer mechanism.
Built to Execute
Our first-in-class solution finally unlocks the full promise of this proven cancer target. With early success in ovarian cancer paving the way, this groundbreaking approach is poised to create a future of broader therapeutic impact. We see tremendous opportunities for extensions into other challenging cancers, including prostate, triple-negative breast cancer (TNBC), and pancreatic cancer.
Efficacy Profile
Oral in vivo POC in ovarian cancer, and additional data in other tumors
Demonstrated Synergy
Powerful combinations with approved therapies such as PARPi, immunotherapy, and chemotherapy
Vast Potential
Promising early data as a single agent and in combination across multiple tumor types
Partnering Opportunities
Our commitment at Grannus is to translate leading-edge science into tangible clinical benefit for patients. Whether you are an institutional investor seeking impactful opportunities or a medical professional interested in cutting-edge science, we welcome the opportunity to connect.
Please reach out for more information.
Grannus Therapeutics.
A member of our team will be in touch.